#CURRENT US TIMING FULL#
#CURRENT US TIMING SERIES#

Vaccine doses should be administered by the intramuscular route.Īt least 8 weeks after last monovalent doseĢ doses monovalent Moderna and 1 dose bivalent Moderna

#CURRENT US TIMING SERIES#

However, for COVID-19 vaccination there are exceptions for children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 to 5 years during the 3-dose vaccination series and children who transition from age 5 years to 6 years during the Moderna COVID-19 vaccination series (see Transitioning from a younger to older age group).įor additional guidance on vaccination in specific situations, see Considerations for extended intervals for COVID-19 vaccine doses and COVID-19 vaccination and SARS-CoV-2-infection. In general, CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination in accordance with the recommended intervals for that age group ( 1). The monovalent Novavax COVID-19 Vaccine remains authorized for use as a 2-dose primary series and as a booster dose in certain limited situations. People ages 12 years an older who previously received 1 or 2 monovalent Novavax primary series dose(s) are recommended to receive 1 bivalent mRNA vaccine dose. People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1 or more additional bivalent mRNA vaccine doses.People ages 6 months and older who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses, depending on age and vaccine product.At the time of initial vaccination, people ages 6 months and older are recommended to receive 3 bivalent mRNA doses.People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine doseįor people who are moderately or severely immunocompromised:.

People ages 6 years and older who are unvaccinated or previously received only monovalent vaccine doses are recommended to receive 1 bivalent mRNA vaccine dose.At the time of initial vaccination, depending on vaccine product, children ages 6 months–4 years are recommended to receive 2 or 3 bivalent mRNA vaccine doses children age 5 years are recommended to receive 1 or 2 bivalent mRNA vaccine doses.The number of bivalent doses varies by age, vaccine, previous COVID-19 vaccines received, and the presence of moderate or severe immune compromise.įor people who are not moderately or severely immunocompromised: Overview of the COVID-19 vaccination scheduleĬDC recommends that people ages 6 months and older receive at least 1 bivalent mRNA COVID-19 vaccine.Īn overview of COVID-19 vaccination is summarized below detailed schedules can be found in Table 1 for people who are not moderately or severely immunocompromised and in Table 2 for people who are moderately or severely immunocompromised. See Appendices A ( People who received COVID-19 vaccine outside the United States) and B ( People who received COVID-19 vaccine as part of a clinical trial) for recommendations for these populations. CDC recommends that people stay up to date with COVID-19 vaccination. There is currently no FDA-authorized COVID-19 vaccine for children younger than age 6 months.

#CURRENT US TIMING FULL#

COVID-19 Vaccine Product Information can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.ĬOVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. None of the currently FDA-authorized COVID-19 vaccines are live-virus vaccines.ĬOVID-19 vaccine-specific FDA fact sheets and U.S. Janssen COVID-19 Vaccine is no longer available in the United States. Novavax COVID-19 Vaccine is formulated as a monovalent vaccine based on the original (ancestral strain) of SARS-CoV-2. The monovalent formulations of the two mRNA COVID-19 vaccines (COMIRNATY/Moderna COVID-19 Vaccine and SPIKEVAX/Pfizer-BioNTech COVID-19 Vaccine) should no longer be used for COVID-19 vaccination.Īll currently available mRNA COVID-19 vaccines in the United States are formulated as a bivalent vaccine based on the original (ancestral) strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 (BA.4/BA.5) variants of SARS-CoV-2. Pfizer-BioNTech COVID-19 Vaccine, Bivalent.The following COVID-19 vaccines, categorized into three vaccine types, are currently authorized under an EUA by FDA and available for use in the United States:

Current us timing